Phase 4Completed

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma

Sponsor
Novartis Pharmaceuticals (Industry)
Enrollment
10 enrolled
Conditions
Renal Angiomyolipoma
Interventions
Everolimus
Ages
adults, older adults
Registry
NCT05252585

Full record on ClinicalTrials.gov

From the registry

The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) . Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.

Primary outcomes

  • Percentage of participants with adverse events (AEs), Serious AEs (SAEs) and AEs of special interest (AESI)

History

  1. Enrollment up to 10

    , from 4 to 10

  2. Last registry update

  3. Completed

    , from Active, not recruiting to Completed

  4. Primary completion

  5. Started

  6. Registered